Iodine-131–labeled Meta-Iodobenzylguanidine Therapy of Children with Neuroblastoma: Program Planning and Initial Experience

Patients with high-risk neuroblastoma have a poor prognosis, especially in cases of recurrent or relapsed disease. Iodine-131–labeled meta-iodobenzylguanidine (131I-MIBG) can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. Establishing an MIBG therapy program requires a great deal of planning, availability of hospital resources, and the commitment of individuals with training and expertise in multiple disciplines. Providing 131I-MIBG therapy requires physical facilities and procedures that permit patient care in compliance with the standards for occupational and community exposure to radiation. Establishment of a successful 131I-MIBG therapy program also requires a detailed operational plan and appropriate education for caregivers, parents, and patients.